Vivo Bio Tech share news, announcements and annual reports
NSE: VIVOBIOTBSE: 511509Pharmaceuticals & BiotechnologySmall Cap
Vivo Bio Tech Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1994
Last close ₹13.87down ₹0.31 (2.19%)BSE ₹13.85
Share price at the NSE close on 28 Oct 2026. Previous close ₹14.18.
28 Oct: open ₹14.18, high ₹14.39, low ₹13.38
52-week range of BSE trades to 28 Oct 2026
₹12.20Low, 26 Oct 2026₹35.76High, 13 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹31 Cr3,302nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.33
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −3.3%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹0.60 crore of one-off items, the largest of them in the quarter to Mar 2026.
- −2.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 5.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.72
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 15,01869.0% delivered
Vivo Bio Tech board meetings
135 filed, newest first. Page 1 of 3.
Aug 2026
22 Aug · Board meeting
Jul 2026
7 Jul · Board meeting
Meeting on 13 Jul 2026: quarterly results
Jun 2026
29 Jun · Board meeting
24 Jun · Board meeting
May 2026
29 May · Board meeting
Meeting on 30 May 2026: audited results25 May · Board meeting
Meeting on 29 May 2026: scheme of arrangement and audited resultsNot held on this date
Feb 2026
2 Feb · Board meeting
Meeting on 13 Feb 2026: quarterly results
Nov 2025
4 Nov · Board meeting
Meeting on 14 Nov 2025: quarterly results
Aug 2025
26 Aug · Board meeting
6 Aug · Board meeting
Meeting on 12 Aug 2025: quarterly results
Jul 2025
2 Jul · Board meeting
Meeting on 2 Jul 2025: increase in authorised capital2 Jul · Board meeting
Jun 2025
11 Jun · Board meeting
Meeting on 11 Jun 2025
May 2025
19 May · Board meeting
13 May · Board meeting
Meeting on 19 May 2025: audited results
Jan 2025
2 Jan · Board meeting
Meeting on 9 Jan 2025: issue of warrants, preferential issue of shares and quarterly results
Nov 2024
18 Nov · Board meeting
Meeting on 21 Nov 2024: employees stock option plan
Oct 2024
29 Oct · Board meeting
Meeting on 14 Nov 2024: quarterly results
Aug 2024
26 Aug · Board meeting
10 Aug · Board meeting
1 Aug · Board meeting
Meeting on 10 Aug 2024: quarterly results
Jun 2024
18 Jun · Board meeting
Meeting on 18 Jun 2024
May 2024
6 May · Board meeting
Meeting on 20 May 2024: audited results
Feb 2024
Jan 2024
30 Jan · Board meeting
Meeting on 12 Feb 2024: quarterly results
Nov 2023
3 Nov · Board meeting
Meeting on 14 Nov 2023: quarterly results
Sep 2023
18 Sep · Board meeting
Meeting on 21 Sep 2023: preferential issue of shares
Aug 2023
Jul 2023
24 Jul · Board meeting
Meeting on 7 Aug 2023: quarterly results